THRX: I have to correct myself here. The remaining THRX would hold more respiratory assets than I initially thought after further examination. They not only hold their own LAMA program TD4208, but also those MABA programs partnered with GSK. So it is still attractive hold IMO.
Market Data 
Markets 
AI
